PD-L1 testing was performed using the PD-L1 IHC 22C3 pharmDx assay; a tumor proportion score (TPS) ≥1% was deemed to be positive and TPS <1% negative (indeterminate results were excluded from the analysis). The gene discussed is CD274; the disease is neoplasm.